



**Innovative cardiovascular company Xeltis nominates Michel Darnaud for election to its Board of Directors**

Zurich, Switzerland, 18 May 2015 -- [Xeltis](#), a privately-held medical device company dedicated to transforming standards of care in cardiovascular treatments, announced that its Board of Directors has nominated Michel Darnaud to stand for election at the company's Annual Meeting of Shareholders currently scheduled for June 1, 2015. Michel Darnaud is a medical device veteran with more than 30 years in leadership roles at major cardiovascular device companies.

"With its game-changing technology, Xeltis is setting a new industry benchmark in the cardiovascular field, a worldwide growth market. I look forward to participating to the development of such a disruptive new player", says Michel Darnaud.

Xeltis has developed a completely new therapeutic category called Endogenous Tissue Growth, or ETG, in which surgeons use synthetic bioabsorbable implants designed to allow the body to repair itself by growing natural, healthy tissue from the inside, leaving nothing behind as the implant is absorbed. Because the tissue produced through ETG is the patient's own, the treatment has the potential to stretch the boundaries of current standards of care.

"We are on a mission to transform standards of care in cardiovascular treatments by replacing permanent prostheses by a new generation of bioabsorbable devices. We believe our technology will have a profound, positive impact on clinical practice, benefiting both patients and physicians. We are delighted that Michel has agreed to join Xeltis to help the company deliver on this promise." states Laurent Grandidier, CEO of Xeltis.

Prior to joining Sorin Group in February 2008 as President of Cardiopulmonary and Intercontinental business, Michel Darnaud spent time at Spencer Stuart, after having been President Europe for Boston Scientific for seven years. Before Boston Scientific, Michel spent 18 years with Baxter International, where he worked his way up to the position of President of the European Cardiovascular Business. Michel is also a former Chairman of Eucomed, the European Medical Device Industry Association. Michel is currently Chairman of public company Stentys.

**About Xeltis**

Xeltis is a European medical device company dedicated to transforming standards of care in cardiovascular treatments and is based in Zurich, Switzerland, and Eindhoven, The Netherlands. Investors include Life Sciences Partners, Amsterdam (LSP), Kurma Partners, Paris (Kurma), VI Partners, Zug (VI) and private shareholders. Xeltis' first product will be a replacement valve for children born with a congenital heart malformation requiring replacement of their pulmonary valve. Ultimately, the company's technology has potential for broad application across a number of cardiovascular conditions and patient populations.

- Ends -

For more information: visit [www.xeltis.com](http://www.xeltis.com)



Media contact:  
Danièle Castle  
Genevensis Healthcare Communications  
T: + 41 79 202 6667  
E: [info@genevensis.com](mailto:info@genevensis.com)